More positive coverage but still major concerns
The article's headline is positive but anyone with concerns about end points is not going to be reassured. The article states: "Although promising, it should be noted that there were changes made to the design of the trial. Less than 2 weeks ago, the trial information on the NIH registry site was updated from phase 2 to phase 3, with RSBQ as the new primary end point rather than a secondary outcome, as it was originally. Prior to the changes, maximum plasma concentration, PK AUC, lipid panels, and significant laboratory findings, such as incidence of AEs, were the primary outcome measures.2 The company did not report how the drug fared on the original main end point in this data release."
Anavex needs to provide the data for the original end points (primary and secondary). Since the design of the study was to gather this information- I don't believe they could not provide it. Until they do this, there is going to be doubt hanging over the study. I'm very pro-Anavex and don't see why they can't do this. If for some solid scientific reason they cannot, they should clearly explain why a study designed to answer a set of questions can no longer do so. If the reason is that they didn't pay for the data analysis to do so, they need to immediately get the analysis performed.